COVID-19 vaccination in Israel.
COVID-19 vaccination in Israel.
复制标题
DOI：
10.1016/j.cmi.2021.07.041
复制
发表时间：
2021-11
期刊：
影响因子：
--
通讯作者：
Cohen D
中科院分区：
文献类型：
--
作者：
Muhsen K;Cohen D
2019年12月，关于2019冠状病毒病（COVID-19）的病原——严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）出现的初步报告发表。自那时以来，COVID-19在全球造成了大量发病率和死亡率。从2020年12月到2021年初，几种COVID-19疫苗在许多国家获得了监管部门的批准。以色列的人口超过900万。大约74%是犹太人（其中近12%是极端正统（宗教）），21%是阿拉伯人，5%是其他宗教和种族。以色列的医疗保健制度的特点是全民健康保险。根据卫生部的规定，通过四个保健组织（病人基金）向所有公民提供一揽子广泛的保健服务。每个公民必须是这些通过社区诊所提供初级保健服务的病人基金之一的成员。住院服务一般由公立医院提供，相关费用由病人基金支付。所有患病基金都保留电子健康记录，并拥有发达的物理和虚拟基础设施以及与成员的沟通途径。
Initial reports on the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the aetiological cause of coronavirus disease 2019 (COVID-19), were published in December 2019. Since then, COVID-19 has resulted in substantial morbidity and mortality globally [1]. From December 2020 through the beginning of 2021, several COVID-19 vaccines received regulatory authorization in many countries.The population of Israel includes more than nine million people. Approximately 74% are Jews (of which nearly 12% are ultraorthodox (religious)), 21% are Arabs and 5% are of other religions and ethnicities [2]. The healthcare system in Israel is characterized by universal health insurance. Under the regulation of the Ministry of Health (MoH), a broad basket of health services is provided to all citizens through four health maintenance organizations (sick funds). Each citizen must be a member of one of these sick funds that supply primary care services via community clinics. Inpatient services are generally provided by public hospitals, with associated costs covered by the sick funds [3]. All sick funds maintain electronic health records and have well developed physical and virtual infrastructure and paths of communication with their members.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
168.9
作者：
Clarfield, A. Mark;Manor, Orly;Israeli, Avi
通讯作者：
Israeli, Avi
DOI：
10.15585/mmwr.mm7027e2
发表时间：
2021-07-09
期刊：
MMWR. Morbidity and mortality weekly report
影响因子：
--
作者：
Gargano JW;Wallace M;Hadler SC;Langley G;Su JR;Oster ME;Broder KR;Gee J;Weintraub E;Shimabukuro T;Scobie HM;Moulia D;Markowitz LE;Wharton M;McNally VV;Romero JR;Talbot HK;Lee GM;Daley MF;Oliver SE
通讯作者：
Oliver SE
影响因子：
13.8
作者：
Chodick G;Tene L;Patalon T;Gazit S;Ben Tov A;Cohen D;Muhsen K
通讯作者：
Muhsen K
影响因子：
5.5
作者：
Abu Mouch S;Roguin A;Hellou E;Ishai A;Shoshan U;Mahamid L;Zoabi M;Aisman M;Goldschmid N;Berar Yanay N
通讯作者：
Berar Yanay N